S. 1095 · 119th Congress

Stop STALLING Act

Introduced on Mar 24, 2025 by Amy Klobuchar (D-MN). 6 cosponsors, 2 of them from another party. Latest action (Apr 10, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Stage
Reported by committee
Introduced
Mar 24, 2025
Cosponsors
6
2 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Subjects

  • Administrative remedies
  • Business ethics
  • Civil actions and liability
  • Competition and antitrust
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Licensing and registrations
  • Prescription drugs
  • Public participation and lobbying

Summary

By the Congressional Research Service (Introduced in Senate, Mar 24, 2025). Public domain.

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Amy KlobucharD-MNSponsor

Democrats · 4

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Mar 24, 2025Introduced in Senate
  2. Mar 24, 2025 · SenateRead twice and referred to the Committee on the Judiciary.
  3. Apr 3, 2025 · SenateCommittee on the Judiciary. Ordered to be reported without amendment favorably.
  4. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
  5. Apr 10, 2025 · SenateCommittee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
  6. Apr 10, 2025 · SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 45.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA15 reports
    $57.5M reported (all issues)
  2. AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)6 reports
    $25.6M reported (all issues)
  3. BCBSM, Inc.6 reports
    $176K reported (all issues)
  4. Blue Cross and Blue Shield Association6 reports
    $7.5M reported (all issues)
  5. Blue Cross and Blue Shield of Florida, Inc.6 reports
    $710K reported (all issues)
  6. Campaign for Sustainable Drug Pricing (CSRxP)6 reports
    $300K reported (all issues)
  7. GSK (fka GLAXOSMITHKLINE INC.)6 reports
    $7.4M reported (all issues)
  8. GUIDEWELL MUTUAL HOLDING CORPORATION6 reports
    $40K reported (all issues)
  9. NOVARTIS CORPORATION6 reports
    $13.1M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  10. TEVA PHARMACEUTICALS USA, INC.6 reports
    Federal contractor: TEVA PHARMACEUTICALS USA, INC.$25.9M in contracts, FY2026AI match · 100%
  11. The Campaign for Sustainable Rx Pricing6 reports
    $540K reported (all issues)
  12. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION5 reports
    $16.8M reported (all issues)
  13. BIOTECHNOLOGY INNOVATION ORGANIZATION4 reports
    $6.4M reported (all issues)
  14. BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.4 reports
    $40K reported (all issues)
  15. COUNCIL FOR INNOVATION PROMOTION (C4IP)4 reports
    $360K reported (all issues)
  16. Families USA Foundation, Inc.4 reports
    $38K reported (all issues)
  17. T1INTERNATIONAL USA4 reports
  18. AARP3 reports
    $15.6M reported (all issues)
  19. KAISER FOUNDATION HEALTH PLAN INC.3 reports
    $1.6M reported (all issues)Federal contractor: KAISER FOUNDATION HEALTH PLAN OF WASHINGTONAI match · 97%
  20. BLUECROSS BLUESHIELD OF TENNESSEE2 reports
    $360K reported (all issues)
  21. Public Citizen2 reports
    $172.6K reported (all issues)
  22. AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES1 report
    $700K reported (all issues)
  23. ASSOCIATION FOR ACCESSIBLE MEDICINES1 report
    $650K reported (all issues)
  24. BLUE CROSS BLUE SHIELD OF MICHIGAN1 report
    $266K reported (all issues)
  25. Blood Cancer United (FKA The Leukemia & Lymphoma Society)1 report
    $590K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.